Shafeeq S Ladha MD

Neurology•Phoenix, AZ

Neuromuscular Medicine, Neurophysiology

Director, Gregory W. Fulton ALS and Neuromuscular Disease Center

Join to View Full Profile

240 W Thomas RdSuite 400Phoenix, AZ 85013
Phone+1 602-406-6262
Fax+1 602-406-6261

Education & Training

Mayo Clinic College of Medicine and Science (Phoenix)Fellowship, Clinical Neurophysiology, 2005 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Neuromuscular Medicine (Neurology), 2004 - 2005
Barrow Neurological Institute at St Joseph's Hospital and Medical CenterResidency, Neurology, 2001 - 2004
Barrow Neurological Institute at St Joseph's Hospital and Medical CenterInternship, Neurology, 2000 - 2001
University of Arizona College of MedicineClass of 2000

Certifications & Licensure

AZ State Medical License 2002 - 2026
MN State Medical License 2004 - 2006
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

Top Doctors:Arizona State Castle Connolly, 2013

Clinical Trials

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2008 Apr 01
Completed
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers Start of enrollment: 2011 Nov 01
Completed
International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
COMPLETED
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Start of enrollment: 2014 Oct 01
Completed
Phase 4
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Start of enrollment: 2015 Jun 01
Completed
Phase 2
A Trial of Tocilizumab in ALS Subjects Start of enrollment: 2015 Nov 01
Completed
Phase 2
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Start of enrollment: 2015 Sep 03
Completed
Phase 3
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation Start of enrollment: 2016 Aug 29
Completed
Phase 2
Deep Phenotyping in Patients With ALS Start of enrollment: 2017 Feb 07
Completed
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2021 Aug 16
TERMINATED
PHASE3
Join now to see all

Publications & Presentations

PubMed

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.
, Jinsy Andrews, Sabrina Paganoni, Eric A Macklin, Lori B Chibnik
JAMA Neurology. 2025-04-01
1 citations
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis.
Alexandra Lovett, Sowmya Chary, Suma Babu, Gaëlle Bruneteau, Jonathan D Glass
Muscle & Nerve. 2025-02-27
2 citations
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
, James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17

Journal Articles

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
Brian J Wainger, Nicholas J Maragakis, Richard Bedlack, Namita A Goyal, Seward B Rutkove, Michael H Rivner, Stephen A Goutman, Shafeeq S Ladha, Elizabeth A Mauricio, R..., JAMA Neurology
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Michael A Elliott, Samuel Maiser, Margaret A Owegi, Stephen A Goutman, Carlayne E Jackson, Jeffrey D Rothstein, Edward J Kasarskis, Liberty Jenkins, ..., The New England Journal of Medicine

Press Mentions

Healthcare AI Company and Neurological Center Collaborating on New Tool to Improve ALS ManagementJanuary 8th, 2019

Professional Memberships